Mary Switzer
Adult Health · Selma, ALNPI 1831574003
Payments from drug & device makers
Across 163 payments — averaging $14.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$585
- Otsuka America Pharmaceutical, Inc.$316
- Novartis$272
- Novo Nordisk$195
- Bayer$146
- AstraZeneca$124
- plus $649 from 18 others
What the payments were for
- Food & beverage$2,287100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 62 | $585 |
| Otsuka America Pharmaceutical, Inc. | 18 | $316 |
| Novartis | 18 | $272 |
| Novo Nordisk | 11 | $195 |
| Bayer | 9 | $146 |
| AstraZeneca | 6 | $124 |
| GSK | 7 | $118 |
| Shield Therapeutics Inc | 4 | $73 |
| Lundbeck LLC | 2 | $54 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $53 |
| Boehringer Ingelheim | 4 | $52 |
| Pfizer | 3 | $40 |
| Sunovion Pharmaceuticals Inc. | 2 | $38 |
| Mylan Specialty L.p. | 2 | $29 |
| Neurocrine Biosciences, Inc. | 1 | $28 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $25 |
| Genentech USA, Inc. | 2 | $23 |
| Dexcom, Inc. | 1 | $20 |
| Sumitomo Pharma America, Inc. | 2 | $20 |
| Astellas Pharma US Inc | 1 | $17 |
| Lilly USA, LLC | 1 | $17 |
| Exact Sciences | 1 | $16 |
| Ironwood Pharmaceuticals, Inc | 1 | $15 |
| Merck | 1 | $13 |
How this compares
$2,287 in reported general payments places this provider in the 75th percentile of 308 adult health providers in Alabama.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 67 | $73,189 |
| OzempicSemaglutide | 43 | $52,691 |
| FarxigaDapagliflozin Propanediol | 44 | $25,868 |
| LinzessLinaclotide | 12 | $12,798 |
| Tresiba Flextouch U-200Insulin Degludec | 18 | $12,113 |
| JardianceEmpagliflozin | 12 | $8,934 |
| PremproEstrogen,con/M-Progest Acet | 12 | $2,755 |
| Prednisone | 231 | $2,354 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 49 | $1,591 |
| Duloxetine Hcl | 48 | $1,529 |
| Pravastatin Sodium | 59 | $1,514 |
| Diclofenac Sodium | 74 | $1,304 |
| Amlodipine Besylate | 179 | $1,216 |
| Hydroxyzine Hcl | 35 | $979 |
| Verapamil SrVerapamil Hcl | 13 | $975 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $17 | $73,18967 claims |
| Novo NordiskOzempic | $195 | $52,69143 claims |
| AstraZenecaFarxiga | $124 | $25,86844 claims |
| AbbVieLinzess | $585 | $12,79812 claims |
| Boehringer IngelheimJardiance | $52 | $8,93412 claims |
| PfizerPrempro | $40 | $2,75512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 308 adult health providers in Alabama.
Other adult health in Selma
- Wendy CantrellMountain Brk$276K
- Lanier OhareBirmingham$42K
- Jessica WrightBirmingham$33K
- Sara HopperBirmingham$21K
- Andrea SuttonBirmingham$21K
- Olivia ViseHoover$15K
- Lindsay SmithPelham$14K
- Alaina OdomAlabaster$14K
- Holly CluckMontgomery$12K
- Ashley YorkHoover$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.